Mayo Clinic | Strategic Alliance Partners

Stephen M. Ansell, MD, PhD, discusses recent progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.

Jeremy C. Jones, MD, discusses key lessons learned from the phase 3 KEYNOTE-177 trial.

Jeremy C. Jones, MD, discusses targeting HER2 alterations in colorectal cancer.

Wen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.

Shaji K. Kumar, MD, discusses the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.

Jeremy C. Jones, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in colorectal cancer.

Tanios Bekaii-Saab, MD, spotlights the recent developments made in gastrointestinal cancers.

Joleen M. Hubbard, MD, discusses the utility of minimal residual disease assessment for stage II colorectal cancer.

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

Daniel H. Ahn, DO, shares how to navigate among the therapeutic options available for patients with advanced, unresectable hepatocellular carcinoma.

Jeremy C. Jones, MD, discusses the clinical utility of pembrolizumab in microsatellite instability–high colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the uptake of precision medicine in colorectal cancer.

Daniel H. Ahn, DO, discusses the utility of atezolizumab in combination with bevacizumab in hepatocellular carcinoma.

Jeremy C. Jones, MD, discusses the importance of testing for microsatellite instability high in colorectal cancer.

Sikander Ailawadhi, MD, discusses the rationale to evaluate lisaftoclax in chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses the activity of lisaftoclax in patients with hematologic malignancies.

The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers.

Joleen M. Hubbard, MD, discusses the potential for treatment with immunotherapy alone in patients with colorectal cancer.

Stephen M. Ansell, MD, PhD, discusses challenges with positron emission tomography scans in patients with Hodgkin lymphoma.

Shaji K. Kumar, MD, discusses the evolving role of venetoclax in relapsed/refractory multiple myeloma.

The National Comprehensive Cancer Network guidelines for the management of frontline and relapsed/refractory multiple myeloma were updated to incorporate novel agents and combination strategies, providing a wide range of category 1 recommended therapies for patients.

Tanios S. Bekaii-Saab, MD, FACP, discusses the challenges of utilizing chemotherapy-free regimens in colorectal cancer.

Donald W. Northfelt, MD, MS, FACP, discusses the progress made with CDK4/6 inhibitors in the treatment of patients with ER-expressing breast cancer and pivotal trials that have moved the needle forward.

Shaji K. Kumar, MD, discusses the challenges of selecting therapy for patients with heavily pretreated multiple myeloma.

Tanios S. Bekaii-Saab, MD, FACP, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer.

Yttrium-90 glass microspheres administered in a personalized, dosimetric approach demonstrated a 16-month improvement in overall survival compared with a standard dosimetric approach in patients with unresectable hepatocellular carcinoma.

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

Tanios S. Bekaii-Saab, MD, FACP, shares his approach for treating patients with HCC across several lines of therapy, as well as factors to consider when making sequencing decisions.

Joleen M. Hubbard, MD, discusses identifying disease progression in patients with colorectal cancer.